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Abstract 
 
Low-molecular-weight Heparins (LMWHs) are being preferred to unfractionated Heparin (UFH) because of their superior 
convenience and comparable or slightly better toxicity profile. This study was designed to investigate and compare the effects 
of LMWH (Bemiparin) and Heparin on hemodynamic parameters, liver and renal function tests and platelet indices of salt-
loaded uninephrectomized hypertensive rats. The experimental rats divided into two groups. The first group included 18 
hypertensive rats. Hypertension induced by unilateral nephrectomy and high NaCl loading with 4% NaCl in diet for 4 weeks. 
The rat models were subdivided into three groups, each subgroup consists of six rats. The first subgroup served as a positive 
control. The second subgroup received a daily intraperitoneal (I.P) injection (250 unit/kg) of Bemiparin for thirty days. The 
third sub group received daily I.P injection (250 unit/kg) of Heparin for thirty days. The second group included six rats 
underwent sham operated surgery and served as a control group. Blood pressure was recorded in conscious rats by the tail-cuff 
plethmography method. At the end of the experiments, blood samples were collected from the rats for determination of serum 
creatinine, blood urea nitrogen, serum total bilirubin, serum sodium, potassium, calcium, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase (ALP) concentrations and platelet indices. Compared to sham control 
rats, Systolic blood pressure in uninephrectomized loaded with a high salt was significantly reduced by administration of both 
Bemiparin and Heparin. Serum K
+ and Na
+ levels of hypertensive rats were significantly increased. Bemiparin significantly 
lowered serum K
+ and Na
+ levels of uninephrectomized rats, while Heparin did not change serum K
+ and Na
+ levels. The rise 
in  both  blood  urea  and  serum  creatinine  of  salt-loaded  uninephrectomized  hypertensive  rats  were  significantly  (P<0.05) 
reduced by Bemiparin and Heparin administration. There were no significant changes in the liver function tests and platelet 
indices of all the experimental rats. The results suggest that Bemiparin has more beneficial effects than Heparin in improving 
blood pressure and renal functions by affecting serum levels of sodium, creatinine and urea. Unlike Heparin, Bemiparin did not 
lead to hyperkalemia in hypertensive rats. 
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Introduction 
 
Heparin,  a  commonly  used  anticoagulant  agent,  is 
frequently used for the prophylaxes and treatment of deep 
venous  thromboembolism.  As  with  most  medications, 
Heparin has a significant side effect profile. Two of its most 
important  side  effects,  major  bleeding  and  hyperkalemia, 
may  be  devastating  without  immediate  diagnosis  and 
treatment (1,2). 
Treatment  with  Heparin  has  beneficial  effects  in 
diabetic  nephropathy  (3).  Heparin  also  has  inhibitory 
effects  on  smooth  muscle  cell  proliferation  and  may  be 
useful  for  long  term  treatment  of  patients  with 
atherosclerosis with the aim of regression of atherosclerotic 
lesions  (4).  Reantragoon  et  al  (5),  demonstrated  that 
Heparin  suppresses  thrombin  stimulated  endothelin-1 
production in endothelial cells which is consistent with its 
reported effects of lowering blood pressure. 
LMWHs  are  being  preferred  to  unfractionated  UFH 
because of their superior convenience and comparable or 
slightly better toxicity profile. Bemiparin sodium is a new 
second-generation LMWH. Bemiparin has the lowest mean 
molecular weight (3600 Da), the longest half-life (5.3 h) 
and the largest antifactor Xa: antifactor IIa ratio (8:1) of all 
LMWHs (6). The distinctive characteristics of LMWH have 
resulted in decreased rates of bleeding and equivalent rates 
of thrombocytopenia compared with UFH (7). LMWH has 
evident advantages over conventional Heparin with chronic 
renal  failure  and  concomitant  arterial  hypertension  (8). 
LMWH  showed  favorable  out  come  in  bleeding  time, 
whole blood clotting time prothrombin time, platelet count, 
fibrinogen, blood urea and serum creatinin (9). Furthermore 
Deepa  and  Varalakshimi  found  that  decreased 
concentration of serum albumin and increased serum urea, 
uric acid and creatinin concentration were normalized by 
LMWH  treatment  (10).  Animal  studies  have  shown  that 
both  Heparin  and  LMWH  decrease  bone  necrosis  (11). 
Moreover, Olayinka, (12) concluded that LMWH can lead 
to  hyperkalemia.  However,  Korea-Michowtiz  etal  (13) 
explained  that  the  effect  of  LMWH  on  serum  potassium 
may be aldosteron independent. 
Abdel Salam et al. (14) demonstrated that total serum 
bilirubin  was  increased  in  rats  treated  with  conventional 
Heparin;  while  alkaline  phosphates  was  higher  after 
LMWH  treatment.  Their  results  suggested  a  beneficial 
effect  for  nadroparin  and  enoxaparin  in  the  treatment  of 
patients  with  obstructive  jaundice  or  cholestatic  liver 
disorders (14). Few studies have yet been conducted to test 
the  effects  of  UHF  and  LMWH  on  blood  pressure, 
electrolytes,  and  liver  and  renal  function  tests  in 
nephroctomized salt loaded rats. The aim of this study was 
to investigate the beneficial and adverse effects of LMWH 
(Bemiparin)  and  Heparin  in  experimentally  induced 
hypertensive rats.  
 
Materials and methods 
 
Animals 
Male albino rats (Rattus norvegicus) weighing 300-375 
grams  were  used  in  the  present  study.  During  the 
experimental period, six animals were kept in each cage. 
The room temperature was maintained at 25 ºC. A 12 hr 
light/dark cycle was set (15). Rodent food rich in nutrient 
and tap water were supplied.  
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Experimental design 
The  experimental  rats  were  divided  into  two  groups. 
The first group included 18 rats which were fed a high-salt 
diet  (4%  NaCl),  for  4  weeks  and  underwent 
uninephrectomy (16). The animals were
 allowed to survive 
after  each  operation  and  were  monitored  in
  the 
postoperative  period  with  daily  weights  and  close 
observations
  of  their  behavior.  The  rat  models  were 
subdivided into three groups, each subgroup having six rats. 
The first subgroup served as a positive control. The second 
subgroup  received  a  daily  I.P  injection  (250  mg/kg)  of 
Bemiparin  for  thirty  days.  The  third  sub  group  received 
daily I.P injection (200 mg/kg) of UFH for thirty days. The 
second  group included six  rats  underwent sham  operated 
surgery and served as a control group. 
 
Blood pressure and heart rate measurements 
Systolic  blood  pressure  (SBP)  and  heart  rate  were 
measured  by  the  tail-cuff  plethymography  method  in 
unanaesthetized rats prewarmed for 20 minutes at 37 °C in 
a thermostatically control heating cabinet. The tail pressure 
pulsations were detected with a pneumatic pulse transducer 
(ADInstruments, power lab 2/25).  
Animals  were  adapted  to  the  blood  pressure 
measurement procedure three times before the first pressure 
recording was made. Pressure and heart rate values were 
obtained by averaging 3-4 individual readings. 
 
Chemical analysis 
At the end of the experiment, rats were sacrificed, blood 
samples were collected and sera were separated from whole 
blood samples immediately by centrifugation. Serum AST, 
ALT,  ALP,  creatinine,  urea,  total  bilirubin  and  calcium 
were  estimated  spectrophtometerically  by  their  standard 
biochemical kits (BIOLABO, France). Serum sodium and 
potassium  were  determined  by  flame  photometry 
(JENWAY, Model 8515 PFP 7). 
 
Statistical analysis 
All data are expressed as means± standard error (M±SE) 
and  statistical  analysis  was  carried  out  using  statistically 
available software (SPSS Version 11.5). Data analysis was 
made using one-way analysis of variance (ANOVA). The 
comparison among groups done using Duncan test. P<0.05 
was considered as statistical significance. 
 
Results 
 
Statistical analysis revealed that, SBP was significantly 
increased  (P<0.01)  in  salt-loaded  uninephrectomized  rats 
(132.16 ± 2.414 mm Hg) compared to the control group 
(110.86 ± 2.963 mm Hg). Administration of Heparin (250 
units/kg/day)  and  Bemiparin  (250  units/kg/day)  for  thirty 
days  to  hypertensive  rats  resulted  in  significantly 
decreasing  blood  pressure  in  both  Bemiparin-treated 
hypertensive  rats  (110.63  ±  2.777  mm  Hg)  and  Heparin 
treated hypertensive rats (116.61 ± 3.44 mm Hg) (Table 1). 
Compared to the control group (297.6 ± 7.05 BPM), the 
heart  rate  was  also  significantly  higher  in  salt-loaded 
nephrectomized  rats  (349.08  ±  15.55  BPM).  Both 
Bemiparin  and  Heparin  administration  were  unable  to 
significantly  change  heart  rate  of  salt-loaded 
nephrectomized rats (Table 1). 
 
Table 1: Effects of Bemiparin and Heparin on systolic blood pressure and heart rate in salt loaded nephrectomized rats (n=24). 
 
Treatment  Systolic BP 
(mm Hg) 
Heart rate 
(beat/minute.) 
Control  110.86±2.9630
a  297.6±7.0506
a 
Salt loaded uninephrectomized rats  132.16±2.4141
b  349.08±15.5551
b 
Salt loaded nephrectomized rats + Bemiparin  110.63±2.7774
a  316.2±16.9557
ab 
Salt loaded nephrectomized rats + Heparin  116.61±3.4433
a  314.8±9.4496
ab 
Different letters indicate significant difference at P<0.05. 
 
Serum  calcium  tended  to  increase  in  salt-loaded 
nephrectomized  rats,  Bemiparin  and  Heparin  failed  to 
attenuate  the  rise  in  serum  calcium  (Table  2).  Serum 
sodium  levels  of  salt-loaded  nephrectomized  rats  were 
markedly increased. Administration of a daily I.P injection 
of  (250  mg/kg)  of  Bemiparin  significantly  (P<0.05) 
lowered serum sodium. Heparin significantly increased the 
serum potassium (5.580 ± 0.1356 meq/l) level of salt loaded 
nephrectomized  rats.  Compared  to  the  positive  control 
group  (4.520  ±  0.2332  meq/l)  Bemiparin  did  not 
significantly  change  serum  potassium  (4.780  ±  0.1530 
meq/l) concentration.  
Neither salt-loaded nephrectomized rats nor Bemiparin 
and Heparin significantly changed serum AST and ALT, 
while serum alkaline phosphatase tended to increase in salt-
loaded  nephrectomized  rats  from  35.175±  3.7929  in  the 
control  group  to  66.00±  4.3302  in  the  salt-loaded 
nephrectomized  rats.  Bemiparin  treatment  of  salt-loaded 
nephrectomized  rats  did  not  alter  serum  alkaline 
phosphatase,  while  daily  I.P  injection  of  Heparin  (200 
mg/kg)  for  thirty  days  caused  a  small  insignificantly Iraqi Journal of Veterinary Sciences, Vol. 25, No. 1, 2011 (15-20)  
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reduction  in  its  serum  level,  whereas,  no  statistical 
differences were detected in serum total bilirubin in all the 
treated groups (Table 3). 
Our results demonstrate that both blood urea and serum 
creatinine  were  reduced  significantly  (P<0.05)  by 
Bemiparin and Heparin administration (Table 3) 
Unilateral nephrectomized and NaCl treated rats did not 
show  significant  change  in  platelet  count,  mean  platelet 
volume  (MPV)  and  plateletcrit  (PCT)  relative  to  control 
group.  Moreover,  Bemiparin  and  Heparin  treated  salt-
loaded nephrectomized rats did not change platelet indices 
as seen in (Table 4). 
 
Table 2: Effects of Bemiparin and Heparin on serum calcium sodium and potassium in salt loaded nephrectomized rats (n=24). 
 
Treatment  Serum calcium (mg/dl)  Serum Na
+ (meq/l)  Serum K
+ (meq/l) 
Control  8.1500±0.1284
a  149.4±2.4113
a  5.120 ± 0.243
ab 
Salt loaded uninephrectomized rats  8.7000±0.1140
b  165.0±0.9486
c  4.520 ± 0.2332
a 
Salt loaded nephrectomized rats + Bemiparin  8.6250±0.0487
b  155.8±2.9223
ab  4.780 ± 0.1530
a 
Salt loaded nephrectomized rats + Heparin  8.5400±0.1600
b  159.6±3.3407
bc  5.580 ± 0.1356
b 
Different letters indicate significant difference at P<0.05. 
 
Table 3: Effects of Bemiparin and Heparin on liver and kidney function tests in salt loaded – nephrectomized rats (n=24). 
 
Treatment  ALT 
(U./ml) 
AST 
(U./ml) 
ALP 
(U./L) 
Blood 
urea 
mg/dl 
Serum 
creatinine 
mg/dl 
Serum total 
bilirubin 
mg/dl 
Control  16.1501± 
0.2224 
a 
20.125± 
0.2416
 a 
35.175± 
3.7929
 a 
25.805± 
0.3489
 b 
0.3000± 
0.0836
 a 
0.1250± 
0.0193
 a 
Salt loaded uninephrectomized rats  16.6001± 
0.8074
 a 
20.300± 
1.1410
 a 
66.00± 
4.3302
 c 
25.300± 
1.1887
 b 
2.0400± 
0.7187
 b 
0.1200± 
0.0200
 a 
Salt loaded nephrectomized rats + Bemiparin  16.750± 
0.3041
 a 
20.325± 
0.1391
 a 
58.200± 
3.8131
 bc 
15.400± 
1.3293
 a 
0.5000± 
0.0316
 a 
0.1250± 
0.0194
 a 
Salt loaded nephrectomized rats + Heparin  16.100± 
0.6753
 a 
20.160± 
1.1655
 a 
54.040± 
1.1289
 b 
14.300± 
0.4147
 a 
0.7800± 
0.2709
 a 
0.1200± 
0.0200
 a 
Different letters indicate significant difference at P<0.05. 
 
Table 4: Effects of Bemiparin and Heparin on platelet indices in salt loaded – nephrectomized rats (n=24). 
 
Treatment  Platelet count (x10
3/µL)  MPV (fL)  PCT(%) 
Control  581.4±4.802
a  4.8000±0.2302
a  0.2940±0.0128
a 
Salt loaded uninephrectomized rats  651.01±15.381
a  4.6800±0.1319
a  0.2740±0.0270
a 
Salt loaded nephrectomized rats + Bemiparin  523.4±107.87
a  4.3200±0.2477
a  0.2180±0.0371
a 
Salt loaded nephrectomized rats + Heparin  537.01±35.396
a  4.2800±0.1881
a  0.2380±0.0239
a 
Different letters indicate significant difference at P<0.05, MPV = Mean platelet volume, PCT = Plateletcrit. 
 
Discussion 
 
The results of the present study showed that unilateral 
nephrectomy  along  with  salt  diet  increased  SBP.  This 
elevation in blood pressure may be result from peripheral 
vasoconstriction and a decrease in renal blood flow and 
GFR (17). Several studies found that the mechanisms by 
which salt increases BP may result from an alteration in 
renin-angiotesin  and  nitric  oxide  (NO)  levels,  increased 
oxidative stress and damage to kidneys (18,19). Whereas, 
Vasdev et al. (20), suggested that insulin resistance may be 
a  major  mechanism by  which  high salt intake  increases 
blood  pressure.  High  salt  intake  increases  insulin 
resistance,  a  condition  strongly  associated  with 
hypertension  due  to  excess  production  of  endogenous 
aldehyde. 
Bohlerder et al. (21) and Kobori et al. (22) concluded 
that renovascular and salt loaded hypertension may be due 
to  increased  Ag  II  rather than  rennin.  A  previous study 
demonstrated  that  high  salt  intake  along  with  unilateral 
nephrectomy  (UNx)  produced  accelerated  hypertension 
within  3-4  weeks  in  dogs  (23).  Experimental  studies 
confirmed  that  renal  damage  greatly  enhanced  by 
uninlateral  nephrectomy  and  high  salt  diet  (24). 
Hypertension  that  was  detected  in  salt-loaded 
nephrectomized rats was reduced and returned close to the Iraqi Journal of Veterinary Sciences, Vol. 25, No. 1, 2011 (15-20)  
 
19 
  
control  values  by  both  Bemiparin  and  Heparin 
administration.  Reantragoon  et  al.  (5)  demonstrated  that 
Heparin  suppresses  thrombin-stimulated  endothelin-1 
production in endothelial cells which is consistent with its 
reported effect of lowering blood pressure. On the other 
hand,  the  available  evidence  showed  that  LMWH  has 
advantages over conventional Heparin in the conservative 
treatment of patient with glomerulonephrits, with chronic 
renal failure and concomitant arterial hypertension (6).  
The  mechanism  by  which  Bemiparin  reduces  blood 
pressure is not well understood. One possible hypothesis is 
that Heparin could reduce blood pressure through rennin-
angiotensin-aldosteron system rather than the involvement 
of sympathetic nervous system which can increase heart 
rate elevation. Both Bemiparin and Heparin administration 
did not significantly change heart rate. 
 Results  of  the  current  study  revealed  that  serum 
sodium  and  potassium  were  increased  in 
uninephrectomized rats that received 4% NaCl. Johnson et 
al.  (25)  demonstrated  interstitial  accumulation  of 
Agngiotensin  II  positive  cells  as the  reason for primary 
sodium retention in patients with nephrotic syndrome.  
It is well known that renal effects of Agngiotensin II 
include a decreased glomerular filteration rate which will 
reduce  the  filtered  sodium  load,  an  increase  in  tubular 
sodium  reabsorption  and  impairment  of  pressure 
natriuresis  (26).  In  addition,  decreased  NO  level  in 
uninephrectomized-salt loaded rats resulted in decrease in 
urinary excretion of sodium, potassium and water which in 
turn increase serum levels of sodium and potassium (27). 
Moreover,  Schiffrin  and  St-Louis,  (28)  found  that  atrial 
natriuretic  peptide  receptor  are  down  regulated  after 
sodium loading in uninephrectomized rats.  
Administration  of  Bemiparin  significantly  lowered 
serum  sodium  and  returned  close  to  the  control  values. 
However, unfactionated Heparin could not reduce serum 
sodium significantly. Hyperkalemia that was induced by 
Heparin was not observed in Bemiparin group. This result 
may  be  due  to  that  Heparin  induces  hypoaldosteronism 
leading  to  hyperkalemia  (1).  Interestingly,  for  the  first 
time;  this  result  showed  that  Bemiparin  unlike  other 
LMWH did not cause hyperkalemia. Olaynnka, concluded 
that  LMWH  like  UFH  can  lead  to  hyperkalemia  (12). 
Moreover, short-term treatment with LMWH (nadroparin) 
induces a significant increase in serum potassium level but 
the related incidence of relevant hyperkalemia is low (29).  
Serum  calcium  tended  to  increase  in  salt-loaded 
nephrectomized rats, this is in agreement with the finding 
of Beevers et al. who reported that contraction of smooth 
muscle  cells  is  related  to  a  rise  in  intracellular  Ca+2 
concentration  (30).  Tierney  et  al.  elucidated  that  an 
increase  in  intracellular  Na+  may  lead  to  increased 
intracellular Ca+2 concentrations as a result of facilitated 
exchange  and  might  explain  the  increase  in  vascular 
smooth muscle cells (VSMCs) tone that is characteristic of 
established hypertension (31). Eiam-Ong et al. observed 
that hypercalcemia could influence BP by direct action on 
the VSMCs, or by inducing increments in blood levels of 
various vasopressive substances (32).  
 Neither  salt-loaded  nephrectomized  rats  nor 
Bemiparin and Heparin significantly changed serum AST 
and  ALT,  while  serum  alkaline  phosphatase  tended  to 
increase  in  salt-loaded  nephrectomized  rats.  The  reason 
behind  this  elevation  may  be  due  to  the  necrotic  and 
oxidative  action of liver  tissues  which  cause leakage  of 
these enzymes from hepatocytes as a result of hepatocytes 
membrane  damage  (33). The  results  presented that both 
blood urea and serum creatinine were reduced significantly 
by  daily  intraperitoneal  injection  of  both  Bemiparin  or 
Heparin. Reports related to the effects of LMWH on blood 
urea and serum creatinine are very limited. However, there 
is evidence that decreased concentration of serum albumin, 
urea, uric acid and creatinine were normalized by LMWH 
treatment,  Bemiparin  and  Heparin  treated  salt-loaded 
nephrectomized  rats  did  not  change  platelet  indices 
relative to control group. This finding is consistent with 
the observation of Paul et al. (9) who found a favorable 
outcome  in  bleeding  time,  whole  blood  clotting  time, 
prothrombin time and platelet count.  
 
Conclusions 
 
The results suggest that Bemiparin has more beneficial 
effects than Heparin in improving blood pressure and renal 
functions by affecting serum levels of sodium, creatinine 
and  urea.  Unlike  Heparin,  Bemiparin  did  not  lead  to 
hyperkalemia in nephrectonized salt loaded hypertensive 
rats. 
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